6 / 6
Onkologiekongresse
Dieser Beitrag beinhaltet keine von der Autorin durch-
geführten Studien anMenschen oder Tieren.
Literatur
1. Goss PE et al (2016) A randomized trial (MA.17R)
of extending adjuvant letrozole for 5 years after
completinganinitial5yearsofaromataseinhibitor
therapy alone or preceded by tamoxifen in
postmenopausal women with early-stage breast
cancer.JClinOncol34(suppl):abstrLBA1
2. Lemieux J et al (2016) Patient-reported outcomes
from MA.17R: A randomized trial of extending
adjuvant letrozole for 5 years after completing an
initial 5 years of aromatase inhibitor therapy alone
or preceded by Tamoxifen in postmenopausal
womenwithearly-stagebreastcancer.JClinOncol
34(suppl):abstrLBA506
3. Perry JR et al (2016) A phase III randomized con-
trolled trial of short-course radiotherapy with or
withoutconcomitantandadjuvanttemozolomide
in elderly patients with glioblastoma (CCTG CE.6,
EORTC26062–22061,TROG08.02,NCT00482677).
JClinOncol34(suppl):abstrLBA2
4. van den Bent MJ et al (2016) Results of the
interim analysis of the EORTC randomized phase
III CATNON trial on concurrent and adjuvant
temozolomide in anaplastic glioma without
1p/19q co-deletion: An Intergroup trial. J Clin
Oncol34(suppl):abstrLBA2000
5. Park JR et al (2016) A phase III randomized clinical
trial (RCT) of tandem myeloablative autologous
stemcelltransplant(ASCT)usingperipheralblood
stemcell(PBSC)asconsolidationtherapyforhigh-
riskneuroblastoma(HR-NB):AChildren’sOncology
Group (COG) study. J Clin Oncol 34(suppl):abstr
LBA3
6. Neoptolemos JP et al (2016) ESPAC-4: A mul-
ticenter, international, open-label randomized
controlled phase III trial of adjuvant combina-
tion chemotherapy of gemcitabine (GEM) and
capecitabine (CAP) versus monotherapy gemcita-
bine in patients with resected pancreatic ductal
adenocarcinoma. J Clin Oncol 34(suppl):abstr
LBA4006
7. Venook A et al (2014) CALGB/SWOG 80405: Phase
III trial of irinotecan/5-FU/leucovorin (FOLFIRI)
or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with
bevacizumab (BV) or cetuximab (CET) for patients
(pts) with KRASwild-type (wt) untreatedmetasta-
ticadenocarcinomaofthecolonorrectum(MCRC).
JClinOncol32(suppl):abstrLBA3
8. Lenz H et al (2014) CALGB/SWOG 80405: PHASE
III trial of irinotecan/5-FU/leucovorin (FOLFIRI)
or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with
bevacizumab (BV) or cetuximab (CET) for patients
(pts) TRIAL OF with expanded RAS analysis
untreated metastatic adenocarcinoma of the
colon or rectum (mCRC). ESMO. Ann Oncol
25(suppl):abstr5010
9. Venook AP et al (2016) Impact of primary (1º)
tumor location on overall survival (OS) and
progression-free survival (PFS) in patients (pts)
withmetastaticcolorectalcancer(mCRC):Analysis
of CALGB/SWOG 80405 (Alliance). J Clin Oncol
34(suppl):abstr3504
10. Schwaederle MC et al (2016) Impact of precision
medicine in refractory malignancies: A meta-
analysisof13,203patientsinphaseIclinicaltrials.J
ClinOncol34(suppl):abstr11520
11. Hainsworth J et al (2016) Targeted therapy
for advanced solid tumors based on molecular
profiles: Early results from MyPathway, an open-
label, phase IIa umbrella basket study. J Clin Oncol
34(suppl):abstrLBA11511
12. Palumbo A et al (2016) Phase III randomized
controlled study of daratumumab, bortezomib,
and dexamethasone (DVd) versus bortezomib
and dexamethasone (Vd) in patients (pts) with
relapsed or refractory multiple myeloma (RRMM):
CASTORstudy.JClinOncol34(suppl):abstrLBA4
Der Onkologe